NCEP Statin Recommendations Challenged By CSPI, Researchers
This article was originally published in The Tan Sheet
Executive Summary
The Center for Science in the Public Interest and a cohort of researchers are calling for an independent re-evaluation of the scientific data used by NIH's National Cholesterol Education Program to justify lowering the threshold for statin therapy
You may also be interested in...
Today’s Statin Debate Bears Lessons For Tomorrow’s Cholesterol Drugs
Clinicians recently took to the pages of the Journal of the American Medical Association to argue the appropriateness of using statin therapy as primary prevention in patients who are not already at high risk for a cardiovascular event. Such scrutiny comes as NIH prepares to issue new treatment guidelines to a market newly saturated with popular generic options, and as pharmaceutical companies assess how best to approach the dyslipidemia field.
Mevacor OTC Study Shows High-Risk Users Will “Upstream,” Merck Says
Merck's educational strategy for potential over-the counter sale of 20 mg Mevacor (lovastatin) will prevent rather than increase undertreatment among people who should be using more aggressive statin therapy, the firm contends